Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Sol-Gel Technologies Ltd. (SLGL)

4.68   0.13 (2.86%) 12-05 15:59
Open: 4.55 Pre. Close: 4.55
High: 4.7 Low: 4.55
Volume: 6,347 Market Cap: 108(M)

Technical analysis

as of: 2022-12-06 9:22:01 AM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 5.76     One year: 6.07
Support: Support1: 4.5    Support2: 3.74
Resistance: Resistance1: 4.93    Resistance2: 5.19
Pivot: 4.79
Moving Average: MA(5): 4.68     MA(20): 4.8
MA(100): 5.34     MA(250): 6.11
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 23.4     %D(3): 25.7
RSI: RSI(14): 42.6
52-week: High: 8.51  Low: 3.94
Average Vol(K): 3-Month: 6 (K)  10-Days: 6 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SLGL ] has closed above bottom band by 22.4%. Bollinger Bands are 54% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 36 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.7 - 4.73 4.73 - 4.75
Low: 4.5 - 4.52 4.52 - 4.54
Close: 4.64 - 4.68 4.68 - 4.72

Company Description

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Headline News

Fri, 02 Dec 2022
Is Sol Gel Technologies Ltd (SLGL) Stock Worth a Buy Friday? - InvestorsObserver

Wed, 16 Nov 2022
FY2022 EPS Estimates for Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Cut by HC Wainwright - MarketBeat

Thu, 10 Nov 2022
Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Yahoo Finance

Mon, 07 Nov 2022
What Does Sunshine Biopharma’s Acquisition Of Nora Pharma Mean For The Generic Prescription Drugs Market? - Yahoo Finance

Mon, 26 Sep 2022
Sol-Gel Technologies (NASDAQ:SLGL shareholders incur further losses as stock declines 14% this week, taking one-year losses to 46% - Simply Wall St

Fri, 09 Sep 2022
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 23 (M)
Shares Float 8 (M)
% Held by Insiders 74 (%)
% Held by Institutions 13.9 (%)
Shares Short 123 (K)
Shares Short P.Month 128 (K)

Stock Financials

EPS 0.41
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.18
Profit Margin (%) 28.9
Operating Margin (%) 26.5
Return on Assets (ttm) 10.8
Return on Equity (ttm) 21.3
Qtrly Rev. Growth 279.1
Gross Profit (p.s.) 0.47
Sales Per Share 1.43
EBITDA (p.s.) 0.41
Qtrly Earnings Growth 0
Operating Cash Flow -3 (M)
Levered Free Cash Flow -4 (M)

Stock Valuations

PE Ratio 11.14
PEG Ratio 0
Price to Book value 2.14
Price to Sales 3.26
Price to Cash Flow -37.72

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.